Last reviewed · How we verify
IMM2510
At a glance
| Generic name | IMM2510 |
|---|---|
| Also known as | IMM2510 Injection |
| Sponsor | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors (PHASE1)
- A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors (PHASE1)
- A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer (PHASE2)
- IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMM2510 CI brief — competitive landscape report
- IMM2510 updates RSS · CI watch RSS
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc. portfolio CI